



PositiveID Corporation to Launch Clinical Trial of Its Easy Check Non-Invasive Breath Glucose Detection Device This Month

Easy Check Featured Today in Wall Street Journal Story

DELRAY BEACH, Fla., Jan. 5, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management, announced today it will launch the first clinical trial of its Easy Check™ non-invasive breath glucose detection device for people with diabetes later this month. The clinical trial will initially focus on people with type 2 diabetes. [Easy Check](#) would eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading.

Currently under development in Israel, [Easy Check](#) is a non-invasive breath glucose detection device that measures the level of acetone in a patient's exhaled breath and correlates that acetone level to a measure of blood glucose. The [Easy Check](#) technology is based on a patent-pending reagent cell that mixes a patient's exhaled air with a proprietary chemical compound, triggering a chemical reaction. The reaction is measured and software in the [Easy Check](#) device then interprets the measurement and correlates the patient's acetone level to the level of glucose in the body.

PositiveID Chairman and CEO William J. Caragol, said, "Our development of [Easy Check](#) continues to progress well as evidenced by the imminent launch of our first clinical trial of this potentially revolutionary product later this month. [Easy Check](#) could provide a means for people with diabetes to eliminate the pain associated with taking blood glucose readings, therefore facilitating more frequent testing and improved management of this growing disease."

[Easy Check](#) was featured in a Wall Street Journal story today: <http://blogs.wsj.com/health/2012/01/05/personal-technology-walt-mossberg-on-wireless-enabled-glucometer/>

In November 2011, PositiveID received FDA clearance for iglucose™, a mobile health system for diabetes management. The Company is currently developing [Easy Check](#), GlucoChip™, a continuous glucose sensing microchip, and the iglucose™ glucometer, a blood glucose meter with PositiveID's FDA-cleared [iglucose](#) technology built inside the device.

[iglucose](#) uses wireless technology to empower individuals with diabetes to be more engaged in the self-management of their condition by eliminating the need to keep manual logbooks. [iglucose](#) connects to market leading, data capable glucometers to wirelessly and seamlessly communicate blood glucose readings to the [iglucose](#) diabetes management portal, where, with the user's consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax.

More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at \$200 billion.

About PositiveID Corporation

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=7717>

Statements about PositiveID's future expectations, including the likelihood that the Company will launch the first clinical trial of its Easy Check™ non-invasive breath glucose detection device for people with diabetes later this month; the likelihood that the clinical trial will initially focus on people with type 2 diabetes; the likelihood that Easy Check would eliminate a patient's need to prick his or her finger multiple times per day to get a blood sugar reading; the likelihood that the development of Easy Check continues to progress well as evidenced by the imminent launch of the first clinical trial of this potentially revolutionary product later this month; the likelihood that Easy Check could provide a means for people with diabetes to eliminate the pain associated

with taking blood glucose readings, therefore facilitating more frequent testing and improved management of this growing disease; the likelihood that iglucose uses wireless technology to empower individuals with diabetes to be more engaged in the self-management of their condition by eliminating the need to keep manual logbooks; the likelihood that iglucose connects to market leading, data capable glucometers to wirelessly and seamlessly communicate blood glucose readings to the iglucose diabetes management portal, where, with the user's consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully commercialize iglucose; the Company's ability to complete development of Easy Check and GlucoChip, as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: Allison Tomek

561-805-8000

atomek@positiveidcorp.com



Source: PositiveID Corporation

News Provided by Acquire Media